Navigation Links
DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
Date:2/28/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 28, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to announce the appointment of Mr. John K. Bell to the company's Board of Directors.

John K. Bell , is Chairman of Onbelay Capital Inc., a Canadian based private equity Company with principal investments in Telematics and auto parts manufacturing (for past 5 years). Prior to that, from 1996 to 2005, Mr. Bell was CEO and owner of Polymer Technologies Inc., an automotive parts manufacturer. Prior to that, from 1977 to 1995, Mr. Bell was founder and owner of Shred-Tech Limited a global manufacturer and supplier of industrial shredders and mobile document shredders. Mr. Bell served as interim CEO and director of ATS Automation Tooling Systems in 2007. Mr. Bell is a director of BSM Wireless, Strongco Corporation, and the Royal Canadian Mint. Mr. Bell is National secretary and board member of The Crohns and Colitis Foundation of Canada. Mr. Bell is past Chairman of Waterloo Regional Police, Cambridge Memorial Hospital, Canada's Technology Triangle accelerator network and The Region of Waterloo prosperity counsel. Mr. Bell is a graduate of Western University Ivey School of Business, a Fellow of the institute of Chartered Accountants of Ontario, a graduate of the Institute of Directors Program of Canada and the owner's president program at Harvard and International marketing program at Oxford.

"We are delighted to have John Bell join the DelMar Board. In addition to his extensive financial and accounting background, John's operating experience will be invaluable as we continue to advance our business.  John's skill set and experience complement DelMar's focus on developing and commercializing proven cancer therapies in new orphan drug indications," commented Jeffrey Bacha , President & CEO of DelMar.

About DelMar Pharma

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com;   
or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
4. Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
5. StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
6. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
7. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
9. Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In March
10. Optimer Pharmaceuticals Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer
11. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Kan. , Dec. 7, 2016   Rx Savings ... West Virginia and its Public Employees Insurance Agency ... members access to their innovative healthcare software, ultimately saving money ... with PEIA and provide its members with access to our ... or a more effective, affordable therapy can be found," says ...
(Date:12/7/2016)... Dec. 7, 2016  Varian Medical Systems (NYSE: ... previously announced plans to separate its Imaging Components business.  ... tax-free distribution to Varian stockholders of common stock in ... will hold the Imaging Components business.  As part of ... by the end of January 2017, Varian will receive ...
(Date:12/7/2016)... 7,2016  Based on its recent analysis ... & Sullivan recognizes Nemaura Pharma Limited with ... for Enabling Technology Leadership. Nemaura Pharma,s transdermal ... traditional drug delivery technologies, especially in delivering ... delivery technologies, Memspatch and Micropatch respectively, facilitate ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite is honored to ... the Best New Product Launch category. Gensuite’s entry on their EZ Scan feature ... Global Events & Training Group is a professional event and training provider based ...
(Date:12/7/2016)... ... ... “The Road To Restoration”: an informative and enlightening book for those ... showing of hands. “The Road To Restoration” is the creation of published author, Thomas ... brass ring that you could reach out for, and grab, on the old carousels. ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows readers to tag ... , “Fred Rides a Train” is the creation of published author, Janet Morrison, who ... years in Michigan. The "Fred, the Dog" series is her first attempt at writing ...
(Date:12/7/2016)... ... 2016 , ... Dr. Greg Leyer, the Chief Scientific Officer ... DC workshop on November 2nd. The conference was an opportunity for both probiotic ... regulations. , Dr. Leyer spoke about two main topics at the IPA ...
(Date:12/6/2016)... Ill. (PRWEB) , ... December 06, 2016 , ... ... in their brain networks that can be seen on a type of MRI, ... (PD) is a progressive disorder of the central nervous system characterized by tremors ...
Breaking Medicine News(10 mins):